Since the beginning of the 2021 year, all the main six vaccines against COVID-19 have been used in mass vaccination companies around the world. Virus neutralization and epidemiological efficacy drop obtained for several vaccines against the B. 1.1. 7, B. 1.351 P. 1, and B. 1.617 genotypes are of concern. There is a growing number of reports on mutations in receptor-binding domain (RBD) increasing the transmissibility of the virus and escaping the neutralizing effect of antibodies. The Sputnik V vaccine is currently approved for use in more than 66 countries but its activity against variants of concern (VOC) is not extensively studied yet. Virus-neutralizing activity (VNA) of sera obtained from people vaccinated with Sputnik V in relation to internationally relevant genetic lineages B. 1.1. 7, B. 1.351, P. 1, B. 1.617. 2, B. 1.617. 3 and Moscow endemic variants B. 1.1. 141 (T385I) and B. 1.1. 317 (S477N, A522S) with mutations in the RBD domain has been assessed. The data obtained indicate no significant differences in VNA against B. 1.1. 7, B. 1.617. 3 and local genetic lineages B. 1.1. 141 (T385I), B. 1.1. 317 (S477N, A522S) with RBD mutations. For the B. 1.351, P. 1, and B. 1.617. 2 statistically significant 3.1-, 2.8-, and 2.5-fold, respectively, VNA reduction was observed. Notably, this decrease is lower than that reported in publications for other vaccines. However, a direct comparative study is necessary for a conclusion. Thus, sera from “Sputnik V”-vaccinated retain neutralizing activity against VOC B. 1.1. 7, B. 1.351, P. 1, B. 1.617. 2, B. 1.617. 3 as well as local genetic lineages B. 1.1. 141 and B. 1.1. 317 circulating in Moscow.